Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP -5.26%91 Future 3-5Y EPS without NRI Growth Rate is 27.67 as of Aug. 21, 2026. GuruFocus rates ASX:AFP with a GF Score™ of 91/100 and a GF Value™ of A$3.47 (Fairly Valued). The stock has 6 warning signs investors should review. Among 233 Drug Manufacturers companies, AFT Pharmaceuticals ranks better than 73.82% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, AFT Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate is 27.67.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
AFT Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate Related Terms
ASX:AFP vs ZTS, UTHR, VTRS: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 27.67 mean?
AFT Pharmaceuticals (ASX:AFP) has a Future 3-5Y EPS without NRI Growth Rate of 27.67 as of Aug. 21, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #61 out of 233 companies in the Drug Manufacturers industry, placing it in the top 26.2%.
Is AFT Pharmaceuticals' Future 3-5Y EPS without NRI Growth Rate too high?
AFT Pharmaceuticals' current Future 3-5Y EPS without NRI Growth Rate is 27.67. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 17.14. AFT Pharmaceuticals' value of 27.67 is 61.4% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #61 out of 233 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Future 3-5Y EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #61 out of 233 companies for Future 3-5Y EPS without NRI Growth Rate. This puts AFT Pharmaceuticals in the upper half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.14. AFT Pharmaceuticals' value of 27.67 is 61.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 17.14, based on 233 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Future 3-5Y EPS without NRI Growth Rate of 27.67 is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Future 3-5Y EPS without NRI Growth Rate is 27.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.47, compared to a current price of A$3.60 — trading 3.7% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 27.67 and 61.4% above the Drug Manufacturers industry median of 17.14. AFT Pharmaceuticals' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Future 3-5Y EPS without NRI Growth Rate is 27.67 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of A$3.60 is trading 3.7% above its estimated GF Value™ of A$3.47.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Future 3-5Y EPS without NRI Growth Rate: 27.67
GF Value™: A$3.47 vs. price of A$3.60 (3.7% above fair value)
Industry Position: 61.4% above the Drug Manufacturers median (#61 of 233)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
91GF Score
Get the complete analysis for ASX:AFP
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
